Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$64.20M |
$1.24
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$64.13M |
$1.15
+0.88%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$62.65M |
$1.18
-2.89%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$60.31M |
$11.17
-0.80%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
AAME
Atlantic American Corporation
Bankers Fidelity provides health insurance products (Medicare supplement and group health), expanding L&H offerings.
|
$59.15M |
$3.05
+1.33%
|
|
CDIX
Cardiff Lexington Corporation
Nova Ortho & Spine provides diagnostic and related assessment services, aligning with Diagnostics & Lab Services in Healthcare.
|
$58.18M |
$4.32
|
|
BDSX
Biodesix, Inc.
Biodesix's Nodify and VeriStrat are blood-based diagnostic tests, i.e., liquid biopsy products.
|
$57.77M |
$7.89
-5.22%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
LINK
Interlink Electronics, Inc.
Medical devices & biometrics is a target end-market for Interlink’s sensor and printed electronics solutions.
|
$57.26M |
$3.82
-1.29%
|
|
BLGO
BioLargo, Inc.
Clyra Medical infection control products classify BioLargo under Medical Devices & Biometrics.
|
$56.59M |
$0.19
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$54.72M |
$6.29
-5.56%
|
|
QDMI
QDM International Inc.
Health/medical insurance products are distributed via the company’s insurance brokerage activities.
|
$54.57M |
$32.33
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$54.15M |
$7.24
+6.63%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$54.09M |
$11.81
-0.17%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$52.47M |
$4.44
+1.60%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$51.35M |
$4.38
-0.34%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$50.47M |
$3.67
+0.69%
|
|
AIRG
Airgain, Inc.
AT-Flight asset tracker and its healthcare usage aligns Airgain with Medical Devices & Biometrics as a healthcare-oriented device offering.
|
$50.35M |
$4.25
+3.03%
|
|
YI
111, Inc.
Private label medical devices and biometrics offerings under the healthcare product lineup.
|
$49.03M |
$5.60
-2.10%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$48.84M |
$7.94
-3.87%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$47.74M |
$4.08
+4.49%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$47.55M |
$2.04
-0.49%
|
|
NEPH
Nephros, Inc.
FDA-cleared medical devices (infection-control filters) used in hospitals and dialysis centers.
|
$47.49M |
$4.47
+2.05%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$46.56M |
$1.47
+0.34%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$45.99M |
$1.74
+6.75%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$45.86M |
$0.00
|
|
LVTX
LAVA Therapeutics N.V.
LAVA Therapeutics operates in oncology biotech, developing cancer therapies based on its Gammabody platform.
|
$45.77M |
$1.65
-5.17%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$45.40M |
$6.17
-0.48%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$45.14M |
$0.89
-0.46%
|
|
NRXS
NeurAxis, Inc.
Core product line: Neuromodulation devices (IB-Stim PENFS).
|
$45.05M |
$4.62
+0.54%
|
Showing page 28 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
